Florida is currently home to 3831 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: AdventHealth Altamonte Infusion Center, Altamonte Springs, Florida
Conditions: Breast Cancer
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Recruiting
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Recruiting
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, approximately 35 days 2. 42-day Treatment Period 3. 2-week post do... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Autobahn Site #108, Brandon, Florida
Conditions: Major Depressive Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Tampa, Florida
Conditions: Social Anxiety Disorder (SAD)
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Recruiting
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Colorectal Cancer, Hepatocellular Carcinoma
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/17/2025
Locations: Clinical Neuroscience Solutions, Inc., Jacksonville, Florida
Conditions: Major Depressive Disorder
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
Recruiting
The purpose of this study is to determine how the STRONG intervention compares with usual care for reducing malnutrition among gastroesophageal cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: GastroEsophageal Cancer
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
Recruiting
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
STARLITE for Unresectable High-Grade Gliomas
Recruiting
The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Miami, Miami, Florida
Conditions: High Grade Glioma
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Recruiting
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Mayo Clinic (Cancer Clinical Research Office), Jacksonville, Florida
Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Jacksonville, Florida
Conditions: Social Anxiety Disorder
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: BRCR Medical Center, Plantation, Florida
Conditions: Mature B-cell Malignancies